PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

Drugmaker Pfizer is warning doctors that it expects to run low on supplies of Bicillin L-A, a long-acting injection of the ...

Pfizer has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...